Ischemic Modified Albumin (IMA) as a Novel Marker for Ischemic Heart Disease and Surrogate Marker for Other High Oxidative -Ischemic Conditions

Nepal, Manoj; Jaisawal, Suresh; Guragain, Manish; Kafle, Prakash; Mukkera, Satyanarayana Reddy; Ghimire, Raj Kumar; Simmonds, B. Sangster; Harris, Usman M.; Berger, Stanley

doi:10.5530/jcdr.2017.4.26

Cited by 10 publications

(9 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…People with higher IMA showed longer hospitalization days and had more readmissions as compared to patients with high troponin. However, top high-level IMA did not predict negative cardiovascular events during the hospital stay, while the cTnT test predicted arrhythmia more often than the ACB test [81].…”

Section: іма As a Marker For Diseasesmentioning

confidence: 73%

Ischemia-Modified Albumin: Origins and Clinical Implications

et al. 2021

View full text Add to dashboard Cite

Albumin is one of the most abundant proteins in the body of mammals: about 40% of its pool is located in the intravascular space and the remainder is found in the interstitial space. The content of this multifunctional protein in blood is about 60-65% of total plasma proteins. A decrease in its synthesis or changes of functional activity can destabilize oncotic blood pressure, cause a violation of transporting hormones, fatty acids, metals, and drugs. Albumin properties change under ischemic attacks associated with oxidative stress, production of reactive oxygen species, and acidosis. Under these conditions, ischemia-modified albumin (IMA) is generated that has a reduced metal-binding capacity, especially for transition metals, such as copper, nickel, and cobalt. The method of determining the cobalt-binding capability of HSA was initially proposed to evaluate IMA level and then licensed as an ACB test for routine clinical analysis for myocardial ischemia. Subsequent studies have shown the viability of the ACB test in diagnosing other diseases associated with the development of oxidative stress. This review examines recent data on IMA generation mechanisms, describes principles, advantages, and limitations of methods for evaluation of IMA levels, and provides detailed analysis of its use in diagnostic and monitoring therapeutic efficacy in different diseases.

show abstract

Section: іма As a Marker For Diseasesmentioning

confidence: 73%

Ischemia-Modified Albumin: Origins and Clinical Implications

et al. 2021

View full text Add to dashboard Cite

show abstract

“…It increases in the few minutes after the start of ischemia, rises for 6-12 hours, and returns to normal in 24 hours [18]. Many studies have been published about IMA in acute cardiac and noncardiac ischemic events, however only few studies were related to COPD [7][8][9][10][11][12][13]. Can et al [19] compared serum IMA, ox-LDL (Oxidized Low-Density Lipoprotein), TAS (Total Anti-oxidant Status), and TOS (Total Oxidant Status) levels in 51 patients with stable COPD and 45 healthy cases.…”

Section: Discussionmentioning

confidence: 99%

“…The pathophysiological events of ischemia, including hypoxia and free oxygen radicals changed the N-terminus of albumin, and this molecule is called as IMA [6]. IMA was first discribed as a marker of myocardial ischemia, but now it has been shown that elevated in various states of noncardiac ischemia and oxidative stress conditions such as cerebrovascular diseases, inflammatory bowel diseases, chronic liver diseases, obstructive sleep apnea (OSA) and pulmonary embolism [7][8][9][10][11][12][13].Additionally, it was suggested to be a strong indicator of short-term mortality in patients with end-stage renal disease [14] and myocardial infarction with ST elevation [15].…”

mentioning

confidence: 99%

Is ischemia modified albumin a good marker in acute exacerbation of chronic obstructive pulmonary disease?

Ogan

Evrın

Çandar

et al. 2020

The European Research Journal

View full text Add to dashboard Cite

Objectives: Our aim is to compare the Ischemia modified albumin (IMA) in patients with acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD) with a high oxidative and inflammatory biologic marker like C-reactive protein (CRP) and to investigate its employability in AECOPD and the relationship between arterial blood gas and pulmonary function parameters. Methods: Forty-six patients diagnosed with acute exacerbation of COPD between March 2015-September 2016 at Ufuk University School of Medicine were included. The 1st and 5th days of IMA and CRP levels were measured. Also, IMA levels were given in absorbance units (ABSU). Results: Total 46 patients of COPD, 13 (28.3%) were females and 33 (71.76%) were males. The mean age of the patients was 71.39 ± 10.04 years. The 1st and 5th day values of IMA, ABSU and CRP were 1.08 ± 0.33 and 0.49 ± 0.24; 1.06 ± 0.34 and 0.49 ± 0.26; and 29.25 (3.10-288.00) and 6.35 (0.30-149.00), respectively (p < 0.001). No significant correlation was determined between IMA and CRP. Also, no correlation were determined between the parameters of arterial blood gas and pulmonary function. Conclusions: Although IMA values showed significant increase during acute exacerbation of COPD and decreased after treatment, CRP still appeared more effective in evaluating the exacerbation status and following up of the treatment of patients with COPD.

show abstract

“…Ischemia-modified albumin (IMA) is also one of the novel biomarkers, and its values were altered in conditions of ischemia, inflammation, and high oxidative stress, and, therefore, it has been tested as a potential biomarker for ischemic heart disease [ 18 , 19 ]. According to some studies, IMA can predict mortality in patients with ESRD [ 20 ].…”

Section: Introductionmentioning

confidence: 99%

Biomarkers of Uremic Cardiotoxicity

Stopić

Dragičević

Medić

et al. 2021

Toxins

View full text Add to dashboard Cite

Cardiovascular (CV) morbidity and mortality increase along with the progression of chronic kidney disease (CKD). The potential novel biomarkers of cardiotoxicity have been tested with the aim of the early detection of patients at high CV risk, and among them are markers of inflammation, oxidative stress, acute renal injury, and microRNAs. The study analyzed biomarkers in non-dialysis-dependent (NDD; stage 3a–4 CKD) and dialysis-dependent (DD) CKD patients. The prospective cohort study included 87 patients who were followed for 18 months, during which period newly occurred CV events were recorded. Cox regression analysis confirmed serum albumin, urea, interventricular septum thickness diameter (IVST), the use of calcium antagonist, and erythropoiesis-stimulating agent to be significant predictors of CV outcome. No significant difference was observed in biomarkers of inflammation, oxidative stress, acute kidney injury (IL-18, CRP, ferritin, IMA, SOD, NGAL, and KIM-1), and miR-133a, in regards to the presence/absence of CV event, CV death, and left ventricular hypertrophy. Serum albumin, urea, IVST, and the use of calcium antagonist and erythropoiesis-stimulating agents were confirmed to be factors associated with CV events in CKD patients. Apart from traditional risk factors, new research is needed to define novel and reliable biomarkers of cardiotoxicity in CKD patients.

show abstract

Ischemic Modified Albumin (IMA) as a Novel Marker for Ischemic Heart Disease and Surrogate Marker for Other High Oxidative -Ischemic Conditions

Cited by 10 publications

References 23 publications

Ischemia-Modified Albumin: Origins and Clinical Implications

Ischemia-Modified Albumin: Origins and Clinical Implications

Is ischemia modified albumin a good marker in acute exacerbation of chronic obstructive pulmonary disease?

Biomarkers of Uremic Cardiotoxicity

Contact Info

Product

Resources

About